FY2025 EPS Estimates for Elutia Raised by Cantor Fitzgerald

Elutia Inc. (NASDAQ:ELUT) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Elutia in a report released on Tuesday, August 19th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($0.52) per share for the year, up from their previous forecast of ($0.65). The consensus estimate for Elutia’s current full-year earnings is ($1.74) per share.

Elutia (NASDAQ:ELUT) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The company had revenue of $6.26 million during the quarter, compared to analysts’ expectations of $6.55 million.

Separately, Lake Street Capital lowered their price objective on Elutia from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $8.00.

Elutia Stock Up 5.0%

Shares of ELUT opened at $2.12 on Thursday. Elutia has a 12-month low of $1.61 and a 12-month high of $5.12. The firm has a market capitalization of $87.17 million, a price-to-earnings ratio of -2.00 and a beta of 0.88. The stock’s 50-day moving average price is $2.01 and its 200 day moving average price is $2.29.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. OMERS ADMINISTRATION Corp acquired a new position in shares of Elutia in the 1st quarter worth approximately $28,000. XTX Topco Ltd acquired a new position in shares of Elutia in the 2nd quarter worth approximately $28,000. Northern Trust Corp boosted its holdings in shares of Elutia by 30.0% in the 4th quarter. Northern Trust Corp now owns 17,957 shares of the company’s stock worth $67,000 after acquiring an additional 4,148 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Elutia in the 1st quarter worth approximately $48,000. Finally, Arcus Capital Partners LLC acquired a new position in shares of Elutia in the 1st quarter worth approximately $51,000. 74.03% of the stock is owned by institutional investors and hedge funds.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.